Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002316090 | SCV000847602 | uncertain significance | Inborn genetic diseases | 2016-08-19 | criteria provided, single submitter | clinical testing | The p.C401Y variant (also known as c.1202G>A), located in coding exon 13 of the ATP13A2 gene, results from a G to A substitution at nucleotide position 1202. The cysteine at codon 401 is replaced by tyrosine, an amino acid with highly dissimilar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Fulgent Genetics, |
RCV002477656 | SCV002785014 | uncertain significance | Kufor-Rakeb syndrome; Autosomal recessive spastic paraplegia type 78 | 2021-12-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002477656 | SCV002984426 | likely benign | Kufor-Rakeb syndrome; Autosomal recessive spastic paraplegia type 78 | 2024-09-04 | criteria provided, single submitter | clinical testing |